Ian McCaffery

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.3K citations · Full text

Medicine, Cancer Biology, Oncology +14

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Lawrence Fong, Andrew Hotson, John D. Powderly et al. · Cancer Discovery · 2019 · 339 citations · Full text

Medicine, Immunology, Oncology +17

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

Anthony W. Tolcher, John Sarantopoulos, Amita Patnaik et al. · Journal of Clinical Oncology · 2009 · 307 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma

Manish A. Shah, Yung‐Jue Bang, Florian Lordick et al. · JAMA Oncology · 2016 · 301 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study of Ganitumab, a Fully Human Anti–Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors

William D. Tap, George D. Demetri, Phillip Barnette et al. · Journal of Clinical Oncology · 2012 · 219 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +17